ArticleJournal of virology2000
Soluble receptor-induced retroviral infection of receptor-deficient cells.
Article in Journal of virology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 49 citations in OpenAlex.
- Article
- Retroviral host range extension is coupled with Env-activating mutations resulting in receptor-independent entry.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- The soluble form of the EIAV receptor encoded by an alternative splicing variant inhibits EIAV infection of target cells.PloS one · 2013Article
- The soluble amino-terminal region of HVEM mediates efficient herpes simplex virus type 1 infection of gD receptor-negative cells.Virology journal · 2012Article
- Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery.The Journal of biological chemistry · 2011Article
- Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion.The Journal of biological chemistry · 2011Article
- Simple, automated, high resolution mass spectrometry method to determine the disulfide bond and glycosylation patterns of a complex protein: subgroup A avian sarcoma and leukosis virus envelope glycoprotein.The Journal of biological chemistry · 2011Article
- Insulin degrading enzyme induces a conformational change in varicella-zoster virus gE, and enhances virus infectivity and stability.PloS one · 2010Article
- Receptor binding and low pH coactivate oncogenic retrovirus envelope-mediated fusion.Journal of virology · 2009Article
- Positive and negative regulation of adenovirus infection by CAR-like soluble protein, CLSP.Gene therapy · 2007Article
- Molecular gymnastics at the herpesvirus surface.EMBO reports · 2006Review
- Receptor-independent infection of murine coronavirus: analysis by spinoculation.Journal of virology · 2006Article
- The peptide-binding and ATPase domains of recombinant hsc70 are required to interact with rotavirus and reduce its infectivity.Journal of virology · 2006Article
- Stable association of herpes simplex virus with target membranes is triggered by low pH in the presence of the gD receptor, HVEM.Journal of virology · 2006Article
- Soluble V domain of Nectin-1/HveC enables entry of herpes simplex virus type 1 (HSV-1) into HSV-resistant cells by binding to viral glycoprotein D.Journal of virology · 2006Article
- Phosphatidylserine treatment relieves the block to retrovirus infection of cells expressing glycosylated virus receptors.Retrovirology · 2005Article
- Receptor-induced conformational changes in the SU subunit of the avian sarcoma/leukosis virus A envelope protein: implications for fusion activation.Journal of virology · 2005Article
- Expression and characterization of a soluble, active form of the jaagsiekte sheep retrovirus receptor, Hyal2.Journal of virology · 2005Article
- Heptad repeat 2-based peptides inhibit avian sarcoma and leukosis virus subgroup a infection and identify a fusion intermediate.Journal of virology · 2004Article
- A study of low pH-induced refolding of Env of avian sarcoma and leukosis virus into a six-helix bundle.Biophysical journal · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Current models of retroviral entry hypothesize that interactions between the host cell receptor(s) and viral envelope protein induce structural changes in the envelope protein that convert it to an active conformation, allowing it to mediate fusion with the membrane. Recent evidence supporting this hypothesis is the demonstration that Tva, the receptor for subgroup A avian sarcoma and leukosis virus (ASLV-A), induces conformational changes in the viral envelope protein. These changes include conversion of the envelope protein to an active, membrane-binding state likely representing a fusogenic conformation. To determine whether binding of the soluble Tva (sTva) receptor was sufficient to activate fully the fusogenic potential of the ASLV-A envelope protein, we have evaluated the ability of ASLV-A to infect receptor-deficient cell lines in the presence of sTva. Soluble receptor efficiently mediated infection of cells devoid of endogenous Tva in a dose-dependent manner, and this infection was dependent absolutely on the addition of sTva. The infectivity of the virus was enhanced dramatically in the presence of the polycationic polymer Polybrene or when centrifugal forces were applied during inoculation, resulting in viral titers comparable to those achieved on cells expressing endogenous receptor. sTva functioned to mediate infection at low concentrations, approaching the estimated binding constant of the receptor and viral envelope protein. These results demonstrate that receptor binding can activate the ASLV-A envelope protein and convert it to a fusogenic conformation competent to mediate the fusion of the viral and cellular membranes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.